Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: M04AA03

Febuxostat Krka(febuxostat)

Hyperuricemia;Gout

Marketing Authorisation Holder: Krka, d.d., Novo mesto

EMA Authorisation: 28/03/2019

INN: febuxostat

Indication

Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Krka is indicated in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Febuxostat Krka — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.